Biblio Discovery — Demo Discovery Service

15 hasil untuk "Jason Valent"

Menampilkan 1–15 · 1,14 detik · RSS

  1. Artikel Jurnal

    Myonecrosis in Sickle Cell Anemia—Overlooked and Underdiagnosed

    Nishant Tageja; Marius Racovan; Jason Valent dkk.

    Case Reports in Medicine, Vol. 2010 · 2010 · Inggris · DOAJ Scopus

    Medical literature detailing muscular complications of sickle cell anemia is sparse and limited to a few case-reports. Features consistent with myositis and myonecrosis are often overlooked and patients are inadequately treated, leading to unforeseen complications. We report an interesting case of…

  2. Artikel Jurnal

    Solitary extramedullary plasmacytoma of the penis

    Kyle Scarberry; Armin Jegalian; Jason Valent dkk.

    Urology Annals, Vol. 6 No. 3 · 2014 · Inggris · DOAJ Scopus

    Solitary extramedullary plasmacytomas are rare plasma cell malignancies, particularly outside the upper aerodigestive tract. A 90-year-old male presented with a penile mass suspicious for penile carcinoma. Pathology revealed the tumor to be an Epstein-Barr virus-associated plasmacytoma with no…

  3. Artikel Jurnal

    Utility of Bruton’s Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström’s Macroglobulinemia)

    Maroun Bou Zerdan; Jason Valent; Maria Julia Diacovo dkk.

    Advances in Hematology, Vol. 2022 · 2022 · Inggris · DOAJ Scopus

    Of the variety of immunoglobulin related amyloidosis (AL), immunoglobulin M (IgM) related AL represents only 6 to 10% of affected patients, and the majority of these cases are associated with underlying non-Hodgkin’s Lymphoma including Waldenström’s macroglobulinemia (WM). Ibrutinib, acalabrutinib…

  4. Artikel Jurnal

    Disparities in time to treatment with oral antimyeloma medications

    Hamlet Gasoyan; Faiz Anwer; Jeffrey D. Kovach dkk.

    Blood Cancer Journal, Vol. 14 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract This retrospective cohort study used Taussig Cancer Center’s Myeloma Patient Registry to identify adults with multiple myeloma diagnosed between January 2017-December 2021. Electronic health records data captured time from diagnosis to initial prescription fill for oral antimyeloma…

  5. Artikel Jurnal Teks lengkap

    Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis

    Surbhi Sidana; Mayur Narkhede; Paul Elson dkk.

    PLOS ONE, Vol. 12 No. 3 · 2017 · Inggris · PLOS Scopus

    Introduction: Randomized studies have shown that bortezomib (BTZ) can be given weekly via intravenous (IV) route or twice weekly via subcutaneous (SC) route with lower neuropathy risk and no loss of anti-myeloma efficacy compared to original standard IV twice weekly schedule. Weekly SC should…

    Juga tersedia di: DOAJ

  6. Artikel Jurnal

    Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study

    Majid Jaberi-Douraki; Xuan Xu; Danai Dima dkk.

    Blood Cancer Journal, Vol. 14 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Multiple myeloma (MM) is a complex hematological malignancy of clonal plasma cells driven by alterations to the chromosomal material leading to uncontrolled proliferation in the bone marrow. Ethnic and racial disparities persist in the prevalence, diagnosis, management, and outcomes of MM…

  7. Artikel Jurnal

    Triplet or Quadruplet Regimen Utilization and Overall Survival in Patients Diagnosed With Multiple Myeloma Between 2017 and 2023

    Emily R. Wesley; Faiz Anwer; Michael B. Rothberg dkk.

    eJHaem, Vol. 7 No. 3 · 2026 · Inggris · DOAJ

    ABSTRACT Introduction Multiple myeloma treatment has rapidly evolved, but little is known about the uptake of guideline‐recommended triplet or quadruplet therapy in clinical practice. Methods This retrospective cohort study included adult patients newly diagnosed with multiple myeloma between…

  8. Artikel Jurnal

    Limited duration of dexamethasone in newly diagnosed AL amyloidosis: impact on response, toxicity, and survival

    John Hanna; Hong Li; Ryan Brown dkk.

    Annals of Medicine, Vol. 58 No. 1 · 2026 · Inggris · DOAJ Scopus

    Background Systemic light chain amyloidosis (AL) is a life-threatening disease in which dexamethasone (Dex) is a core therapy but is limited by cumulative toxicity. The optimal duration of Dex, particularly in the era of daratumumab (Dara)-based regimens, is uncertain.Methods We retrospectively…

  9. Artikel Jurnal

    Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis

    Vikram J. Premkumar; Suzanne Lentzsch; Samuel Pan dkk.

    Blood Cancer Journal, Vol. 11 No. 1 · 2021 · Inggris · DOAJ Scopus

    Abstract Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation in light-chain amyloidosis (AL). This retrospective cohort includes 43 patients with previously treated AL, from 14 centers in the US and Europe. Thirty-one patients harbored t(11;14)…